279 related articles for article (PubMed ID: 33658313)
21. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
[TBL] [Abstract][Full Text] [Related]
22. [Developments in the medical treatment of overactive bladder].
Alcántara Montero A
Semergen; 2016; 42(8):557-565. PubMed ID: 26671329
[TBL] [Abstract][Full Text] [Related]
23. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
[TBL] [Abstract][Full Text] [Related]
24. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
Otsuki H; Kosaka T; Nakamura K; Mishima J; Kuwahara Y; Tsukamoto T
Int Urol Nephrol; 2013 Feb; 45(1):53-60. PubMed ID: 23212147
[TBL] [Abstract][Full Text] [Related]
25. Words of Wisdom. Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony).
Cruz F
Eur Urol; 2015 Jun; 67(6):1189-90. PubMed ID: 25944037
[No Abstract] [Full Text] [Related]
26. Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).
Torimoto K; Matsushita C; Yamada A; Goto D; Matsumoto Y; Hosokawa Y; Miyake M; Aoki K; Hirayama A; Tanaka N; Fujimoto K
Neurourol Urodyn; 2017 Apr; 36(4):1097-1103. PubMed ID: 27265880
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial.
Khullar V; Cambronero J; Angulo JC; Wooning M; Blauwet MB; Dorrepaal C; Martin NE
BMC Urol; 2013 Sep; 13():45. PubMed ID: 24047126
[TBL] [Abstract][Full Text] [Related]
28. A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
de Greef-van der Sandt I; Newgreen D; Schaddelee M; Dorrepaal C; Martina R; Ridder A; van Maanen R
Clin Pharmacol Ther; 2016 Apr; 99(4):442-51. PubMed ID: 26422298
[TBL] [Abstract][Full Text] [Related]
29. Mirabegron: A new option in treating overactive bladder.
Turpen HC; Zimmern PE
JAAPA; 2015 Nov; 28(11):16, 18. PubMed ID: 26501573
[TBL] [Abstract][Full Text] [Related]
30. Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
Tyagi P; Tyagi V
IDrugs; 2010 Oct; 13(10):713-22. PubMed ID: 20878594
[TBL] [Abstract][Full Text] [Related]
31. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
[TBL] [Abstract][Full Text] [Related]
32. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.
Sacco E; Bientinesi R; Tienforti D; Racioppi M; Gulino G; D'Agostino D; Vittori M; Bassi P
Expert Opin Drug Discov; 2014 Apr; 9(4):433-48. PubMed ID: 24559030
[TBL] [Abstract][Full Text] [Related]
33. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation.
Rittig S; Baka-Ostrowska M; Tøndel C; Walle JV; Kjaeer B; Passier P; Bosman B; Stroosma O; Tannenbaum S
J Pediatr Urol; 2020 Feb; 16(1):31.e1-31.e10. PubMed ID: 31787582
[TBL] [Abstract][Full Text] [Related]
34. Mirabegron in the treatment of overactive bladder.
Leone Roberti Maggiore U; Cardozo L; Ferrero S; Sileo F; Cola A; Del Deo F; Torella M; Colacurci N; Candiani M; Salvatore S
Expert Opin Pharmacother; 2014 Apr; 15(6):873-87. PubMed ID: 24646053
[TBL] [Abstract][Full Text] [Related]
35. Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?
Fogaing C; Mossa AH; Campeau L
Curr Urol Rep; 2020 Oct; 21(12):49. PubMed ID: 33090278
[TBL] [Abstract][Full Text] [Related]
36. Patient-reported outcomes with the β
Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
[TBL] [Abstract][Full Text] [Related]
37. Re: The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Griebling TL
J Urol; 2015 Mar; 193(3):947. PubMed ID: 25765412
[No Abstract] [Full Text] [Related]
38. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of the combination of KPR-5714, a novel transient receptor potential melastatin 8 (TRPM8) antagonist, and β
Aizawa N; Fujimori Y; Nakanishi O; Hayashi T; Goi Y; Kobayashi JI; Fujita T
Eur J Pharmacol; 2021 May; 899():173995. PubMed ID: 33675781
[TBL] [Abstract][Full Text] [Related]
40. What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?
Caremel R; Loutochin O; Corcos J
Int Urogynecol J; 2014 Feb; 25(2):165-70. PubMed ID: 23922008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
